Skip to main content

Syncom Formulations (India) Limited (SYNCOMF.NS)

National Stock Exchange of India Healthcare Drug Manufacturers - Specialty & GenericView data quality →
55.5Fair

ValueMarkers Composite Index

Top 55%#19,926 of 44,714
Overvalued

217% above intrinsic value ($0)

UndervaluedFair ValueOvervalued
Piotroski
7/9
Strong
Beneish
-1.01
High Risk
Altman
13.40
Safe
DCF Value
$0
Overvalued
ROIC
13.2%
Adequate
P/E
18.2
Fair
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Syncom Formulations (India) Limited (SYNCOMF.NS) — VMCI valuation read

SYNCOMF.NS screens at VMCI 56/100, a 6-point gap above the Healthcare sector median (50). For a mid-cap Syncom Formulations (India) Limited share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.

SYNCOMF.NS has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: SYNCOMF.NS trades at 26.0x earnings, 44% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 1.6x is the rate-sensitivity line to watch, which sets the rate-cycle exposure for Syncom Formulations (India) Limited.

SYNCOMF.NS fell 1.0% over the trailing 7 days, with a -12.6% read on a 30-day basis.

Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It offers various products, including generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, and electrolite. The company also provides histamines, homeostatic, hypoglycemic, hypolipidaemics, local anesthetics, multivitamins and nutritional supplements, sedative anticonvulsants, stimulants, and sympathomimetic products, as well as products used in the treatment of gout. In addition, it engages in the trading of commodities and renting of properties. Further, the company exports its products. It offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquids orals, liquid vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and herbals. Syncom Formulations (India) Limited was founded in 1985 and is based in Indore, India.

CEO: Ankit Kedarmal Bankda998 employeesINwww.syncomformulations.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in SYNCOMF.NS’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.